Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

Gaining EU approval for the use of the biologic atopic dermatitis therapy Dupixent (dupilumab) in adolescents with moderate-to-severe atopic dermatitis, and positive top-line results in children aged six to 11 years with severe atopic dermatitis, will likely cement the lead currently enjoyed by Sanofi and its collaborator, Regeneron Pharmaceuticals Inc., in developing and marketing a biologic for the condition.

However, there are a plethora of biologics in early and late-stage clinical development for atopic dermatitis, indicating the therapeutic segment is likely to become highly competitive in the not-to-distant future...